You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GM-CSF antibody

Showing 1 - 25 of 8,715
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8 With GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 2, 2022

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Neuroblastoma Trial in New York (anti-GD2 murine IgG3 mAb 3F8)

Completed
Has Results
  • Neuroblastoma
  • anti-GD2 murine IgG3 monoclonal antibody 3F8
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Apr 21, 2022

Neuroblastoma Trial in Cologne (antibody ch14.18, GM-CSF, IL-2 i.v.)

Terminated
  • Neuroblastoma
  • antibody ch14.18
  • +4 more
  • Cologne, Germany
    University of Cologne
Nov 3, 2022

Local Progression or Metastatic Melanoma With Failed First-line Treatment Trial in Beijing (Pexa-Vec combined with ZKAB001,

Recruiting
  • Local Progression or Metastatic Melanoma With Failed First-line Treatment
  • Pexa-Vec combined with ZKAB001
  • ZKAB001 monotherapy
  • Beijing, China
    Beijing Cancer Hospital
Mar 30, 2022

Pancreatic Cancer Trial in Baltimore (Cyclophosphamide, GVAX, Pembrolizumab)

Active, not recruiting
  • Pancreatic Cancer
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Jan 5, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer Trial in Detroit (biological,

Completed
  • Metastatic Pancreatic Adenocarcinoma
  • +3 more
  • Aldesleukin
  • +9 more
  • Detroit, Michigan
    Wayne State University/Karmanos Cancer Institute
Mar 30, 2022

Carcinoma, Solid Tumor Trial in China (ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2)

Not yet recruiting
  • Carcinoma
  • Solid Tumor
  • ADC Combined With Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2
  • Changchun, China
  • +18 more
Nov 4, 2021

Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)

Recruiting
  • Neuroblastoma
  • GM-CSF + Naxitamab
  • Gainesville, Florida
  • +22 more
Aug 29, 2022

Neuroblastoma Trial in New York (dietary supplement, drug, biological)

Recruiting
  • Neuroblastoma
  • β-glucan
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 5, 2022

Neuroblastoma Trial (Naxitamab)

Not yet recruiting
  • Neuroblastoma
  • (no location specified)
Sep 18, 2023

Relapsed/Refractory Large B-cell Lymphoma Trial in United States (Cyclophosphamide, Fludarabine, Lenzilumab)

Terminated
  • Relapsed/Refractory Large B-cell Lymphoma
  • Palo Alto, California
  • +9 more
Aug 26, 2022

Renal Cancer Trial in Boston (Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF))

Active, not recruiting
Has Results
  • Renal Cancer
  • Dendritic Cell Tumor Fusion Vaccine
  • Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 2, 2023

Coronavirus Disease 2019 COVID-19 Trial in United States (TJ003234, Placebo)

Completed
  • Coronavirus Disease 2019 COVID-19
  • Little Rock, Arkansas
  • +13 more
May 18, 2022

Melanoma Trial in Beijing (OH2 injection, HX008 injection)

Recruiting
  • Melanoma
  • OH2 injection
  • HX008 injection
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jan 28, 2023

Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)

Terminated
Has Results
  • Platinum Sensitive Ovarian Cancer
  • Ovarian Cancer
  • FRα peptide plus Adjuvant (GM-CSF)
  • Adjuvant (GM-CSF) Alone
  • Birmingham, Alabama
  • +17 more
Nov 21, 2022

Ependymoma, Recurrent Childhood, Ependymoma Trial in Denver, Orlando (Granulocyte Macrophage Colony Stimulation Factor)

Active, not recruiting
  • Ependymoma, Recurrent Childhood
  • Ependymoma
  • Granulocyte Macrophage Colony Stimulation Factor
  • Denver, Colorado
  • +1 more
Feb 8, 2022

Transplant-Related Hematologic Malignancy Trial in Atlanta (Sargramostim, Control Arm)

Recruiting
  • Transplant-Related Hematologic Malignancy
  • Atlanta, Georgia
    Northside Hospital
Oct 19, 2022

Carcinoma, Solid Tumor Trial in Suzhou (ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin)

Not yet recruiting
  • Carcinoma
  • Solid Tumor
  • ADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and Thymopentin
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 26, 2023

Neuroblastoma Recurrent Trial in Worldwide (Naxitamab and GM-CSF in combination with irinotecan and temozolomide)

Terminated
  • Neuroblastoma Recurrent
  • Naxitamab and GM-CSF in combination with irinotecan and temozolomide
  • Hong Kong, Hong Kong
  • +2 more
Nov 8, 2022

Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 1, 2022